Safety of intermittent Pringle maneuver during minimally invasive liver resection in patients with hepatocellular carcinoma with and without cirrhosis

Santiago A. Ortiz Galindo1 · Philipp K. Haber1 · Christian Benzing1 · Felix Krenzien1,2 · Anna Riddermann1 · Oliver Frisch1 · Wenzel Schöning1 · Moritz Schmelzle1 · Johann Pratschke1 · Linda Feldbrügge1,2

Abstract

Purpose The aim of this study was to analyze the impact of minimally invasive intermittent Pringle maneuver (IPM) on postoperative outcomes in patients with hepatocellular carcinoma (HCC) and liver cirrhosis.

Methods In this retrospective cohort study, we evaluated the safety of IPM in patients with HCC who underwent minimally invasive liver resection during five years at our center. Factors influencing the use of IPM were examined in univariate and multivariate regression analysis. Cases with use of IPM (IPM) and those without use of IPM (no IPM) were then compared regarding intraoperative and postoperative outcomes after propensity score matching (PSM) for surgical difficulty.

Results One hundred fifty-one patients underwent liver resection for HCC at our center and met inclusion criteria. Of these, 73 patients (48%) received IPM with a median duration of 18 min (5–78). One hundred patients (66%) had confirmed liver cirrhosis. In multivariate analysis, patients with large tumors (≥ 3 cm) and difficult tumor locations (segments VII or VIII) were more likely to undergo IPM (OR 1.176, \( p = 0.043 \), and OR 3.243, \( p = 0.001 \), respectively). After PSM, there were no differences in intraoperative blood transfusion or postoperative complication rates between the IPM and no IPM groups. Neither did we observe any differences in the subgroup analysis for cirrhotic patients. Postoperative serum liver function tests were not affected by the use of IPM.

Conclusions Based on our findings, we conclude that the use of IPM in minimally invasive liver resection is safe and feasible for patients with HCC, including those with compensated liver cirrhosis.

Keywords Hepatocellular carcinoma · Pringle maneuver · Cirrhosis · Liver resection · Minimally invasive surgery

Introduction

Hepatic inflow occlusion during parenchymal resection, commonly called the Pringle maneuver [1], has been shown to reduce blood loss and improve short-term surgical outcome [2–4], but has also been suspected to cause liver injury due to ischemia–reperfusion damage, based on findings in animal experiments [5, 6]. Several retrospective studies and a few small randomized controlled trials have been published about the efficacy and safety of continuous or intermittent Pringle maneuver (IPM). Nevertheless, the use of Pringle maneuver remains controversial even to this day, with contradictory findings concerning the effects on blood loss and resulting liver injury [7, 8].

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and presents a challenge to liver surgeons, as it most often occurs in cirrhotic livers. Minimally invasive techniques have been widely adopted for minor and increasingly for major liver resection, including for HCC. Several recent studies, including one randomized controlled trial, have compared laparoscopic with open liver resection selectively for HCC patients and have coherently found shorter hospital stay, lower or similar complication rates, and comparable oncologic outcomes [9–11].
Data on safety and efficacy of the Pringle maneuver in minimally invasive surgery are scarce. Most available studies are technical, focusing on partial inflow occlusion or comparing intermittent to continuous occlusion [12–14]. Regarding the use of the Pringle maneuver in cirrhotic livers for HCC resections, findings have been controversial. On the one hand, risk for bleeding is higher in cirrhotic patients, and some studies have found reduction of blood loss [14, 15]. On the other hand, cirrhotic livers may be more vulnerable to ischemia–reperfusion injury [16]. In patients with HCC, who are commonly also diagnosed with liver cirrhosis, the Pringle maneuver has been mostly demonstrated to be safe without a higher incidence of postoperative complications such as postoperative liver failure [4, 17].

The aim of this study was therefore to determine the safety of IPM in minimally invasive liver resection for HCC, with a focus on patients with underlying liver cirrhosis. This topic is highly relevant in times of declining transplantation rates due to organ scarcity, along with a continuous expansion of indication to surgery, including more patients with advanced cirrhosis. Few studies have analyzed outcomes of IPM in minimally invasive liver surgery, and to our knowledge, no publication focused on IPM in minimally invasive liver resections in the special group of cirrhotic HCC patients.

Methods

Study design

In this retrospective cohort study, we analyzed data of all consecutive patients who underwent minimally invasive liver resection for HCC at the Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité—Universitätsmedizin Berlin between January 2015 and December 2020.

The aim was to evaluate the safety of IPM in minimally invasive surgery for HCC, with a focus on patients with underlying liver cirrhosis. Resections that included the use of IPM (IPM) were compared to those performed without IPM (no IPM) with regard to perioperative complications and liver function. A subgroup analysis was performed for patients with liver cirrhosis. To control for potential selection bias, we first determined factors leading to the use of IPM in univariate and multivariate analysis and then performed a propensity score-based matching (PSM) based on these findings. All included patients gave informed consent to the collection of their personal and medical data and its use for research purposes. All data were collected, stored, and processed according to the General Data Protection Regulation and local data protection laws. Cases that lacked conclusive information about use or duration of IPM were excluded. The study was conducted in accord with the ethical standards of the Helsinki Declaration of 1975. The Charité institutional review board approved of the study (EA2/006/16 and EA4/084/17).

Surgical techniques of minimally invasive liver resection and hepatic inflow occlusion

Different minimally invasive access strategies were used in our cohort: Multi-incisional laparoscopic surgery (MILS) was the most common laparoscopic approach, followed by multi-incisional robotic surgery, and, in the early years, hand assisted laparoscopic surgery (HALS) or single-incision laparoscopic surgery (SILS). Surgical techniques of laparoscopic and robotic liver resection are described in details elsewhere [18–20]. In both laparoscopic and robotic surgery, ultrasound was routinely performed intraoperatively to confirm the exact tumor location, borders, and proximity to vascular and biliary structures as well as to rule out further intrahepatic lesions.

IPM was performed using a soft, 3-mm-wide polyethylene terephthalate ribbon that was positioned around the hepatoduodenal ligament before both ends were threaded through a 5-mm trocar on the patient’s left side and externally, through a plastic tube (tourniquet) of approximately 10-cm length. The ends could then be tightened and secured in their position with a clamp at any moment for full inflow occlusion. The anesthesiologist kept a precise log with the respective starting and release times of IPM. Duration of IPM never exceeded 15 min, with a minimum of 5 min reperfusion time between two maneuvers. The decision to use or refrain from IPM was made by the surgeon according to his perceived risk of bleeding. For parenchymal dissection in laparoscopic procedures, we used a water-jet dissector (ERBEJET® 2, Erbe, Tübingen) or an ultrasonic dissector (cavitron ultrasonic surgical aspirator, CUSA, Integra LifeSciences, Saint Priest, France). Other devices, used mostly in combination, were ultrasonic surgical devices with clamp tips such as Harmonic Ace® (Johnson & Johnson, Norderstedt) or THUNDERBEAT (Olympus, Hamburg) or endoscopic linear cutter staplers (Echelon, Johnson & Johnson, USA). In robotic resections, a modified clamp crush technique was applied, using Harmonic ACE®, while large vessels were either clipped or transected using staplers, as in conventional laparoscopic surgery.

Perioperative clinical management and clinical outcome parameters

We determined common patient characteristics such as age, sex, body mass index (BMI), and the general physical status using the American Society of Anesthesiologists’ Physical Status Classification (ASA score). Underlying liver disease
was characterized by etiology; the preoperative model of end-stage liver disease (MELD) score and the histological stage of liver fibrosis with cirrhosis defined as a stage 4 according to Desmet et al. [21] and classified in clinical severity according to the Child Pugh Score. HCC were classified according to size, number of nodules, Milan Criteria [22] and the Barcelona clinic liver cancer (BCLC) classification [23]. Furthermore, the extent (major vs. minor) and the complexity of liver resection as assessed by IWATE classification [24] were determined. Major liver resection was defined as a resection of three or more continuous segments.

After PSM, cases with and without use of IPM were compared with respect to the duration of surgery, need for blood transfusion, length of stay in the hospital after surgery (LOS), length of stay in the intensive care unit (ICU-LOS), postoperative complications (according to Clavien-Dindo classification [25]), textbook outcome [26], post-hepatectomy liver failure (PHLF) as graded according to the International Study Group of Liver Surgery (ISGLS) criteria [27], and resection status (R-classification by pathology). Liver function and hemostatic parameters were assessed by perioperative serum levels of aspartate aminotransferase (AST), aspartate alaninotransferase (ALT), bilirubin, platelet counts, partial thromboplastin time (PTT), and the international normalized ratio (INR). For this, we analyzed one preoperative time point, the first postoperative day (POD1), and the day of or before hospital discharge (pre-discharge). Intraoperative arterial blood gas analysis was measured at the beginning, in the middle and at the end of surgery.

Results

Baseline characteristics and surgical techniques

Between February 2015 and December 2020, 151 minimally invasive liver resections for HCC were performed at our center and met inclusion criteria. With regard to the etiology of the underlying liver disease, we observed 64 cases (42%) of viral hepatitis and 29 (19%) of alcoholic liver disease. Only in 12 cases (8%), the HCC had reportedly occurred in healthy livers. Liver cirrhosis, as determined by histopathology, was present in 100 cases (66%). In 40 cases (27%), HCC was multifocal. Tumor sizes varied with a median of 3 cm (0.3–18 cm) diameter of the largest nodule. The majority of surgeries (78%) were minor resections. Median surgical difficulty as assessed by the IWATE classification was seven, which is considered “advanced” [24]. Thirty-two cases (21%) were operated using the da Vinci Xi surgical system, while the remaining liver resections were conventional laparoscopies. In almost half of the surgeries (48%), IPM was applied during parenchymal resection. The median duration of inflow occlusion among these cases was 18 min (5–78). Baseline characteristics of the patients and tumors and details of the surgical techniques are summarized in Table 1, both for the entire cohort and for matched groups with and without IPM.

Use of IPM in minimally invasive HCC resections

Before analyzing the impact of IPM on perioperative outcome, we aimed to determine potential biases by finding factors that impact the surgeon’s decision to use IPM. Patient, tumor, and surgery-related characteristics were considered. In univariate analysis, we found that IPM was used less frequently in patients who have a poor general status according to ASA as well as in patients with liver cirrhosis (OR 0.485 (0.250–0.939), p = 0.032 and OR 0.364 (0.181–0.732), p = 0.005, respectively). On the other hand, IPM was more likely to be applied in patients with large tumors (OR 2.382 (1.230–4.612), p = 0.010) and those with tumors located in segments VII or VIII, scoring highest in IWATE difficulty score for tumor location (OR 3.228 (1.658–6.283), p = 0.001). Multifocal disease, extent of resection (major vs. minor resection), or the type of surgical access approach (robotic vs. laparoscopic) did not seem to influence the use of IPM (Fig. 1, black bars).

After multivariate analysis using the variables that were significantly associated with the use of IPM in univariate analysis, only tumor size (OR 1.176 (1.026–4.613), p = 0.043) and difficult tumor location (OR 3.243 (1.596–6.589), p = 0.001) independently
predicted the use of IPM during HCC resection (Fig. 1, gray bars). Neither a high ASA score nor underlying liver cirrhosis was significantly associated with avoiding the use of IPM. These findings suggest that technical difficulty is crucial for deciding about the use of IPM and that liver cirrhosis itself does not appear to discourage from applying IPM.
Postoperative complications after minimally invasive HCC resection with and without IPM

To compare perioperative outcomes of minimally invasive HCC resection with and without IPM, we performed a PSM to control for potential selection biases, including the variables that were different in our univariate and/or multivariate analysis. After matching, each group comprised 46 patients. Covariates are balanced well after PSM, as displayed in Supplementary Fig. 1.

Before matching, the median duration of surgery was significantly longer when IPM was applied (difference of 48 min or 25% longer, \( p = 0.001 \)). After PSM, there was no significant difference in duration of surgery, indicating that IPM itself does not prolong surgery, but rather that cases including IPM use were more difficult. The rate of intraoperative red blood cell transfusion in our cohort was 6% with no significant differences between groups before or after PSM. Intraoperative use of IPM did not impact complication rates; overall postoperative morbidity in the whole cohort was 39% with a 15% incidence of severe complication (Clavien-Dindo \( \geq 3a \)), with similar rates of textbook outcome, PHLF, and bile leakage. Patients spent one night (median) on the ICU, and six days in the hospital after surgery, irrespective of undergoing IPM during resection. Ninety-five percent of resections were graded as R0 by the pathologist with no difference between groups. All short-term outcome criteria with and without use of IPM, before and after matching, are detailed in Table 2.

To examine the safety of using IPM in liver cirrhosis, we compared the same short-term outcome parameters between IPM and no IPM in the subgroup of cirrhotic patients, selectively, after performing PSM (Table 3). Before matching, similar to the entire, unmatched cohort, there was a (non-significant) trend towards longer duration of surgery in cases with use of IPM, while all other outcome parameters were similar between the groups. After PSM, there were no significant differences between IPM and no IPM (34 patients per group).

Subgroup analyses were also performed for cases of major resection and long total duration of IPM (\( \geq 30 \) min) and showed no differences between IPM and no IPM, except for a longer duration of surgery in patients who underwent long IPM (Supplementary Tables 1 and 2).

Perioperative liver function in patients with and without undergoing IPM

Serum concentrations of commonly used markers for liver function, AST, ALT, INR, and bilirubin, were all elevated on the first postoperative day (POD1) after liver resection (Fig. 2). While bilirubin decreased to preoperative levels by the time of discharge, AST, ALT, and INR remained slightly elevated, albeit below clinically relevant concentrations. AST shows a tendency to a higher increase postoperatively in patients who undergo IPM, when comparing IPM with no IPM (after PSM, including cirrhotic and non-cirrhotic patients, \( p = 0.072 \)). However, at the time of discharge from hospital, no differences between both groups are longer measurable. ALT, bilirubin, INR, PTT, and platelet counts are similar in both groups at all time points (Fig. 2a).

When analyzing the subgroup of patients with liver cirrhosis, there was no significant difference in serum liver function tests in matched cohorts between IPM and no IPM (Fig. 2b). Postoperative AST levels did not correlate with the duration of IPM in those patients who received IPM, neither the entire group nor in the subgroup of cirrhotic patients (Supplementary Fig. 2).

Intraoperative arterial blood gas analysis showed a temporarily significantly enhanced acidosis in cases of IPM, a
difference that was no longer visible at the end of surgery. Lactate levels at the end of surgery were slightly higher in patients who underwent IPM. The difference in pH, but not in lactate, was also visible in the subgroup of cirrhotic patients (Supplementary Fig. 3).

Discussion

In this retrospective cohort study, we show that IPM during minimally invasive liver resection does not increase perioperative complication rates or risk for liver failure in patients with HCC, including those with liver cirrhosis.

As minimally invasive approaches have become the standard in liver surgery in experienced centers, it is essential to continuously analyze details of the surgical strategies and refine our techniques accordingly. While in the early years, minimally invasive approaches were reserved for benign lesions, minor resections, and mostly healthy patients, indications have been extended over time and now include major resections and patients with substantial liver and systemic disease, such as patients with HCC and underlying liver cirrhosis [9, 29]. We have observed the same development at our own center in the course of ten years and today perform all extents and indications of liver resections minimally invasively, with the exception of surgeries that include vascular or biliary reconstructions [20, 30].

From early on, we have liberally applied a laparoscopic version of the IPM that was well-known from open liver resection and have not noticed complications. However, with more difficult cases and increasingly diseased patients allocated to minimally invasive surgery, it is important to study the safety of IPM objectively, especially as the topic has been discussed so controversially over the years. There are important confounders to consider: We, as most others, use IPM selectively, in roughly 50% of the cases, and these cases are more likely to be difficult, introducing a relevant selection bias. We therefore tested which factors play a role in the surgeon’s decision. In multivariate analysis, the only independent predictors were large tumor size and difficult tumor location, while liver cirrhosis did not seem to discourage from IPM. We then performed a propensity score matching including any factors we had found that may impact the decision for or against IPM. Of course, although controlled for by PSM, a certain heterogeneity in our patient cohort, such as variable tumor size and tumor locations, must be taken into consideration for the interpretation of our data.

Table 2  Intraoperative and postoperative outcome criteria after minimally invasive liver surgery for hepatocellular carcinoma (HCC) with vs. without use of intermittent Pringle maneuver (IPM), before and after propensity score matching (PSM)

| Pre-PSM | Post-PSM |
|---------|----------|
|         | IPM (n=73) | No IPM (n=78) | p | IPM (n=46) | No IPM (n=46) | p |
| Duration of surgery (min) | 240 (102–491) | 192 (49–461) | 0.001 | 231 (102–491) | 196.5 (49–461) | 0.069 |
| Red blood cell transfusion | 6 (8%) | 3 (4%) | 0.315 | 5 (11%) | 3 (7%) | 0.714 |
| Textbook Outcome a | 56 (77%) | 65 (83%) | 0.308 | 32 (70%) | 37 (80%) | 0.229 |
| Postoperative complications b | 26 (36%) | 33 (42%) | 0.400 | 21 (46%) | 24 (52%) | 0.532 |
| Severe complications c, d | 12 (16%) | 10 (13%) | 0.529 | 9 (20%) | 8 (17%) | 0.788 |
| PHLF | 1 (1%) | 3 (4%) | 0.621 | 1 (2%) | 2 (4%) | 1.000 |
| Grade A | 2 (75%) | | | 2 (100%) | | |
| Grade B | 1 (100%) | 1 (25%) | 0.308 | 32 (70%) | 37 (80%) | 0.229 |
| Bile leak | 1 (10%) | 6 (8%) | 0.775 | 4 (9%) | 4 (9%) | 1.000 |
| Post-hepatectomy hemorrhage | 1(1%) | 2 (3%) | 1.000 | 1 (2%) | 2 (2%) | 1.000 |
| Mortality c | 1 (1%) | 0.300 | 1 (2%) | 1.000 |
| LOS, ICU (days) | 1 (0–43) | 1 (0–6) | 0.298 | 1 (0–43) | 1 (0–5) | 0.300 |
| LOS, hospital (days) | 6 (3–61) | 7 (3–26) | 0.345 | 6 (3–61) | 7 (3–26) | 0.686 |
| R0 | 68 (93%) | 75 (96%) | 0.484 | 42 (91%) | 44 (96%) | 0.677 |
| Conversion rate | 1 (1%) | 0.001 | | 1 (2%) | 1.000 |

Data presented as number (percent) for categorical or median (minimum–maximum) for continuous variables. PHLF post-hepatic lesion failure [27], LOS length of stay, ICU intensive care unit, R0 resection status (no residual tumor)

a Defined as no severe complication (≥ 3 according to Clavien-Dindo classification of postoperative complications) [25]; no intraoperative complication ≥ 2 (according to the Oslo classification of intraoperative complications [28]); R0 resection status achieved; no re-admission in 30 days post-discharge; no in-hospital mortality; absence of bile leak grades B or C [26]

b Within 90 days after surgery

c ≥ 3a according to Clavien-Dindo classification of postoperative complications [25]
In the matched cohorts, transfusion rates were comparable with and without IPM, as were postoperative complication rates and all other outcome criteria, with the only exception of pronounced intraoperative acidosis and elevated lactate at the end of surgery. Interestingly, after PSM, there was no difference in liver function tests after surgery at any time point. In the unmatched cohort, transaminase elevation on the first postoperative day was more pronounced in cases of IPM. This indicates that temporary increase in liver cell damage is likely not enhanced by IPM itself, but other factors, such as extent and technical difficulty of resection. Importantly, in the group of patients with liver cirrhosis, there was also no difference in postoperative complications or liver function with regard to use of IPM. Subgroup analysis was also performed for patients with major resection and those cases where IPM duration exceeded 30 min, without finding differences in postoperative outcomes. Of note, we do not report the estimated blood loss as an outcome parameter, but instead focus on the need for transfusion as the best surrogate marker for blood loss, as it denotes those cases with clinically relevant bleeding. In our experience, estimated blood loss can be inaccurate, especially in cases of laparoscopy, where sometimes lavage fluid may remain intra-peritoneally and blood loss is generally low, leading to misleading calculations.

Especially in earlier years of open liver surgery, negative effects of IPM on liver function by ischemia reperfusion injury were postulated, stated as most relevant in patients with pre-existing liver cirrhosis [15]. Two randomized controlled trials that date back more than ten years showed no benefit of IPM and concluded that it should be avoided [31, 32]. However, more recently, an RCT from one of these centers, that included only HCC patients, could not confirm these findings and saw no increase in complications [17]. Several other recent studies report safe use of IPM, some with signs of improved outcomes in patients with HCC in cirrhosis [2, 33]. Our own results corroborate these more recent findings on the safety of IPM. The change in the risk assessment of IPM over the years may well be due to other advances in liver surgery, improving outcomes in general, especially the increased use of minimally invasive approaches.

With regard to minimally invasive IPM, there are several new studies, particularly discussing specific techniques, mostly hemi-hepatic inflow occlusion [12]. One recent study used a comparable technique to ours and similarly concluded that intermittent total hepatic inflow occlusion was

**Table 3** Intraoperative and postoperative outcome criteria after minimally invasive liver surgery for hepatocellular carcinoma (HCC) in the subgroup of patients with liver cirrhosis, with vs. without use of intermittent Pringle maneuver (IPM), before and after propensity score matching (PSM)

|                  | Pre-PSM | Post-PSM |
|------------------|---------|----------|
|                  | IPM     | No IPM   | p       | IPM     | No IPM   | p       |
|                  | n=40    | n=60     |         | n=34    | n=34     |         |
| Duration of surgery (min) | 222 (102–455) | 187 (49–461) | 0.054 | 218 (102–455) | 189 (49–461) | 0.194 |
| Red blood cell transfusion | 4 (10%) | 2 (3%) | 0.214 | 3 (9%) | 2 (6%) | 1.000 |
| Textbook outcomea | 32 (80%) | 50 (83%) | 0.671 | 26 (77%) | 26 (77%) | 1.000 |
| Postoperative complicationsb | 12 (30%) | 23 (38%) | 0.392 | 11 (32%) | 14 (41%) | 0.615 |
| Severe complicationsc,d | 4 (10%) | 7 (12%) | 0.794 | 4 (12%) | 6 (18%) | 0.493 |
| PHLF | 1 (3%) | 2 (3%) | 1.000 | 1 (3%) | 1 (3%) | 1.000 |
| Grade A | 1 (50%) | 1 (50%) | 1.000 |
| Grade B | 1 (100%) | 1 (50%) | 1 (100%) |
| Bile leak | 2 (5%) | 3 (5%) | 1.000 | 2 (6%) | 1 (3%) | 1.000 |
| Post-hepatectomy hemorrhage | 1 (3%) | 1 (2%) | 1.000 | 1 (3%) | 1.000 |
| Mortalitya | 1 (3%) | 0.400 | 1 (3%) | 1.000 |
| LOS, ICU (days) | 1 (0–43) | 1 (0–6) | 0.951 | 1 (0–43) | 1 (0–4) | 0.815 |
| LOS, hospital (days) | 6 (3–42) | 6 (3–26) | 0.507 | 6 (3–42) | 7 (3–26) | 0.218 |
| R0 | 37 (93%) | 57 (95%) | 0.681 | 31 (91%) | 31 (91%) | 1.000 |
| Conversion rate | 1 (2%) | 1.000 | 1 (3%) | 1.000 |

Data presented as number (percent) for categorical or median (minimum–maximum) for continuous variables. PHLF post-hepatectomy liver failure [27], LOS length of stay, ICU intensive care unit, R0 resection status (no residual tumor)

a Defined as no severe complication (≥ 3 according to Clavien-Dindo classification of postoperative complications) [25]; no intraoperative complication ≥ 2 (according to the Oslo classification of intraoperative complications [28]); R0 resection status achieved; no re-admission in 30 days post-discharge; no in-hospital mortality; absence of bile leak grade B or C [26]

b Within 90 days after surgery
c ≥ 3a according to Clavien-Dindo classification of postoperative complications [25]
safe and feasible in laparoscopic liver resection. However, they did not specify the extent of resection in their cohort, making a further comparison with our results difficult [13]. In our study, we focus on the short-term surgical outcomes of minimally invasive HCC resection. However, there is also still debate about long-term, oncological effects: The Pringle maneuver has been suggested to impair oncological outcomes after HCC resection [34, 35], while other studies have shown that IPM is safe without increased risk of early or long-term HCC recurrence [3, 17, 36]. When comparing laparoscopic to open liver resection for HCC in a previous study, we did not find any difference in long-term survival, but did not focus on the use of IPM [37]. Currently, with a short follow-up period and relatively small numbers, especially in the subgroup of patients with liver cirrhosis, it is beyond the scope of this analysis to assess the impact of IPM on oncological long-term outcome, but this question should be followed up and addressed in the future.

In our study, we find that IPM is safe in minimally invasive liver surgery for HCC in cirrhosis. However, as we do not see a relevant decrease in postoperative complication rates or transfusion rates, we cannot conclude that IPM is efficient and no general recommendation for the use of IPM in every case can follow from our findings. This was also not the aim of our study and would have to be examined in a different design, preferably including randomization.

**Conclusion**

We propose that the use of IPM is a safe and useful tool in minimally invasive liver surgery, and does not compromise postoperative liver function, in patients with hepatocellular carcinoma including those with compensated liver cirrhosis.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00423-021-02361-z.

**Acknowledgements** The authors greatly appreciate the contribution of Andrea Köpke, Birgül Ertugrul, and Sabine Boas-Knoop to the study management and data collection.

**Authors’ contributions** Study conception and design: S.A.O.G., L.F., M.S., J.P. Acquisition of data: S.A.O.G., A.R., O.F. Analysis and interpretation of data: S.A.O.G., L.F., P.K.H., M.S., J.P., C.B., F.K., W.S. Drafting of manuscript: S.A.O.G., L.F., M.S. Critical revision of manuscript: S.A.O.G., L.F., P.K.H., C.B., F.K., A.R., O.F., W.S., M.S., J.P.
Funding Open Access funding enabled and organized by Projekt DEAL. The authors acknowledge the support of Intuitive Surgical Deutschland GmbH for providing a research grant for the equipment to perform robotic surgeries and study the outcome. They further acknowledge the support from Deutsche Forschungsgemeinschaft (DFG) to L.F. (FE14.34–2.1) and to M.S. (SCHM2661/3–2) and from Deutscher Akademischer Auslandsdienst (DAAD) to S.A.O.G.

Data availability The data presented are available on request from the corresponding author.

Code availability Not applicable.

Declarations

Ethics approval This cohort study was approved by the Institutional Review Board of Charité (EA2/006/16 and EA4/084/17) and conducted according to the guidelines of the Declaration of Helsinki.

Consent to participate Informed consent was obtained from all subjects involved in this study.

Consent for publication Not applicable.

Conflict of interest Johann Pratschke reports a research grant from Intuitive Surgical Deutschland GmbH. Outside of the submitted work, he reports personal fees or non-financial support from Johnson & Johnson, Medtronic, AFS Medical, Astellas, CHG Meridian, Chiesi, Falk Foundation, La Source Group, Merck, Neovii, NUGGO, pharma-consult Petersen, and proMEDICIS. Moritz Schmelzle reports personal fees or other support outside of the submitted work from Merck, Bayer, ERBE, Amgen, Johnson & Johnson, Takeda, Olympus, Medtronic, and Intuitive. Santiago Andres Ortiz Galindo, Linda Feldbrügge, Philipp K. Haber, Christian Benzing, Felix Krenzien, Anna Riddermann, Oliver Frisch, and Wenzel Schöning have no conflict of interest or financial ties to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Pringle BH (1908) V. Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg 48:541–549
2. Wei X, Zheng W, Yang Z, Liu H, Tang T, Li X, Liu X (2019) Effect of the intermittent Pringle maneuver on liver damage after hepatectomy: a retrospective cohort study. World J Surg Oncol 17:142
3. Al-Saeedi M, Ghamarnejad O, Khajeh E, Shafiei S, Salehpour R, Golriz M, Mieth M, Weiss KH, Longerich T, Hoffmann K, Büchler MW, Mehrabi A (2020) Pringle maneuver in extended liver resection: a propensity score analysis. Sci Rep 10:8847
4. Chau GY, Lui WY, King KL, Wu CW (2005) Evaluation of effect of hemihepatic vascular occlusion and the Pringle maneuver during hepatic resection for patients with hepatocellular carcinoma and impaired liver function. World J Surg 29:1374–1383
5. Iwasaki J, Aify M, Bleilevens C, Klinge U, Weiskirchen R, Steitz J, Vogt M, Yagi S, Nagai K, Uemoto S, Tolba RH (2019) The impact of a nitric oxide synthase inhibitor (L-NAMe) on ischemia(-)reperfusion injury of cholestatic livers by Pringle maneuver and liver resection after bile duct ligation in rats. Int J Mol Sci 20(9):2114
6. Jia C, Dai C, Wang H, Wan Y, Qiao Y, Xu F, Peng S, Zhao Y, Zhao C, Zhao L (2018) Differential effects of three techniques for hepatic vascular exclusion during resection for liver cirrhosis on hepatic ischemia-reperfusion injury in rats. Gastroenterol Res Pract 2018:5309286
7. Fagenson AM, Gleeson EM, Nabi F, Lau KN, Pitt HA (2021) When does a Pringle maneuver cause harm? HPB (Oxford) 23:587–594
8. Hong YP (2020) An invited commentary on “Does the intermittent Pringle’s maneuver lose its clinical value in reducing bleeding during hepatectomy? A systematic review and meta-analysis” [Int. J. Surg. (2020) Epub ahead of print]. Int J Surg 82:4
9. El-Gendi A, El-Shafei M, El-Gendi S, Shawky A (2018) Laparoscopic versus open hepatic resection for solitary hepatocellular carcinoma less than 5 cm in cirrhotic patients: a randomized controlled study. J Laparoendosc Adv Surg Tech A 28:302–310
10. Xourafas D, Pawlik TM, Cloyd JM (2019) Early morbidity and mortality after minimally invasive liver resection for hepatocellular carcinoma: a propensity-score matched comparison with open resection. J Gastrointest Surg 23:1435–1442
11. Ruzzenente A, Bagante F, Ratti F, Alaimo L, Marques HP, Silva S, Soubraze O, Endo I, Sahara K, Beal EW, Lam V, Poulttsides GA, Makris EA, Popescu I, Alexandrescu S, Martel G, Workneh A, Hugh TJ, Guglielmi A, Aldighetti L, Pawlik TM (2020) Minimally invasive versus open liver resection for hepatocellular carcinoma in the setting of portal vein hypertension: results of an international multi-institutional analysis. Ann Surg Oncol 27:3360–3371
12. Zhang Y, Lu X, Xu J, Yang H, Deng X, Chen K, Chen Y (2018) Intermittent Pringle versus continuous half-Pringle maneuver for laparoscopic liver resections of tumors in segment 7. Indian J Surg 80:146–153
13. Peng Y, Wang Z, Wang X, Chen F, Zhou J, Fan J, Shi Y (2019) A novel very simple laparoscopic hepatic inflow occlusion apparatus for laparoscopic liver surgery. Surg Endosc 33:145–152
14. Lan X, Li H, Liu F, Li B, Wei Y, Zhang H, Xu H (2019) Does liver cirrhosis have an impact on the results of different hepatic inflow occlusion methods in laparoscopic liver resection? A propensity score analysis. HPB (Oxford) 21:531–538
15. Wu CC, Hwang CR, Liu TJ, P’Eng FK (1996) Effects and limitations of prolonged intermittent ischaemia for hepatic resection of the cirrhotic liver. Br J Surg 83:121–124
16. Sugiyama Y, Ishizaki Y, Imamura H, Sugo H, Yoshimoto J, Kawasaki S (2010) Effects of intermittent Pringle’s manoeuvre on cirrhotic compared with normal liver. Br J Surg 97:1062–1069
17. Lee KF, Wong J, Cheung SYS, Chong CCN, Hui JWY, Leung VYF, Yu SCH, Lai PBS (2018) Does intermittent Pringle maneuver increase postoperative complications after hepatectomy for hepatocellular carcinoma? A randomized controlled trial. World J Surg 42:3302–3311
18. Wabitsch S, Schönig W, Kästner A, Haber PK, Benzing C, Krenzien F, Lenz K, Schmelzle M, Pratschke J (2021)
A propensity-matched study of full laparoscopic versus hand-assisted minimal-invasive liver surgery. Surg Endosc 35(5):2021–2028

19. Schmelzle M, Schöning W, Pratschke J (2020) Liver surgery - setup, port placement, structured surgical steps - standard operating procedures in robot-assisted liver surgery. Zentralbl Chir 145:246–251

20. Feldbrügge L, Ortiz Galindo SA, Frisch O, Benzing C, Krenzien F, Riddermann A, Kästner A, Nevermann NF, Malinka T, Schöning W, Pratschke J, Schmelzle M (2021) Safety and feasibility of robotic liver resection after previous abdominal surgeries. Surg Endosc

21. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–1520

22. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699

23. Forner A, Hessheimer AJ, Isabel Real M, Bruix J (2006) Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60:89–98

24. Krenzien F, Wabitsch S, Haber P, Kamali C, Brunnbauer P, Benzing C, Atanasov G, Rakayzyan AM, Røsok BI, Edwin B (2013) Morbidity assessment in surgery: refinement proposal based on a concept of perioperative adverse events. ISRN Surg 2013:625093

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.